Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607812 | 0.86 | MEN1 (0.58) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL15607875 | 0.82 | EGFR (0.43) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL9232636 | 0.82 | CA1 (0.70) | EGFRERBB2KDM4EKMT2AALDH1A1 | |
| SCHEMBL16375028 | 0.80 | L3MBTL1 (0.41) | EGFRERBB2KDM4EKMT2AALDH1A1 | |
| SCHEMBL15607809 | 0.78 | MEN1 (0.67) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL15607849 | 0.78 | TAAR1 (0.56) | EGFRERBB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL16375027 | 0.78 | LMNA (0.59) | EGFRERBB2KMT2AMEN1GAA | |
| SCHEMBL16367327 | 0.77 | CHRM1 (0.59) | EGFRERBB2KDM4EALDH1A1GAA | |
| SCHEMBL16374999 | 0.77 | MEN1 (0.65) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL16375308 | 0.76 | EGFR (0.51) | EGFRERBB2KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | EGFR 1866/4885ERBB2 1218/4885KDM4E 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.